DOACs and NOACs in Atrial Fibrillation (AF)

1. DOACs vs. NOACs:

• Terminology: While both terms are often used interchangeably, DOACs is now the more widely accepted term. NOAC, which stands for Non-Vitamin K Antagonist Oral Anticoagulants, was initially used to differentiate these newer anticoagulants from traditional VKAs (Vitamin K antagonists like warfarin), but the term DOAC, which stands for Direct Oral Anticoagulants, better reflects their mechanism of action.
• Mechanism of Action:
  • Dabigatran (Pradaxa): Directly inhibits thrombin (Factor IIa).
  • Rivaroxaban (Xarelto), Apixaban (Eliquis), and Edoxaban (Savaysa): Direct Factor Xa inhibitors.
• Clinical Use: DOACs/NOACs are primarily used for:
  • Stroke prevention in non-valvular atrial fibrillation (AF).
  • Treatment and prevention of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Advantages Over Warfarin:
  • No need for frequent INR (International Normalized Ratio) monitoring.
  • Fewer drug and food interactions.
  • More predictable pharmacokinetics and pharmacodynamics.
  • Lower risk of intracranial bleeding compared to warfarin.

---

2. Mnemonics for Atrial Fibrillation and Stroke Risk:

Causes of Atrial Fibrillation: PIRATES Mnemonic

This helps recall the common causes of AF:

• P: Pulmonary causes (Pulmonary embolism, COPD).
• I: Ischemia (Coronary artery disease, Myocardial infarction).
• R: Rheumatic heart disease (Mitral stenosis).
• A: Alcohol/Anemia.
• T: Thyroid disorders (Hyperthyroidism).
• E: Endocarditis/Electrolyte imbalance.
• S: Sepsis/Stimulants (like caffeine, cocaine).

Risk of Stroke in AF: CHA₂DS₂-VASc Score

Used to assess the risk of stroke in patients with AF, guiding anticoagulation therapy:

• C: Congestive heart failure (1 point).
• H: Hypertension (1 point).
• A: Age ≥ 75 years (2 points).
• D: Diabetes mellitus (1 point).
• S: Stroke or TIA history (2 points).
• V: Vascular disease (1 point).
• A: Age 65–74 years (1 point).
• Sc: Sex category (female) (1 point).

The score is used to decide if anticoagulation is necessary. A score of:

• 0 = No anticoagulation.
• 1 = Consider anticoagulation.
• 2 or more = Strong recommendation for anticoagulation.

Bleeding Risk in AF: HAS-BLED Score

Used to assess the risk of major bleeding in patients on anticoagulation therapy:

• H: Hypertension (1 point).
• A: Abnormal liver or kidney function (1 point each).
• S: Stroke history (1 point).
• B: Bleeding history (1 point).
• L: Labile INR (1 point, relevant if using warfarin).
• E: Elderly (Age > 65) (1 point).
• D: Drugs or alcohol (1 point each).

---

3. The Four Main DOACs/NOACs:

Dabigatran (Pradaxa):

• Mechanism: Direct thrombin (Factor IIa) inhibitor.
• Indications: Stroke prevention in atrial fibrillation (AF), treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Dosage:
  • Normal Dose: 150 mg twice daily.
    • Dabigatran 150 mg twice daily was superior to warfarin in reducing stroke and systemic embolism.
  • Lower Dose: 110 mg twice daily.
    • Dabigatran 110 mg twice daily was non-inferior to warfarin but had a lower risk of major bleeding.
  • Renal Impairment: The dose should be adjusted based on creatinine clearance (CrCl):
    • CrCl 30-50 mL/min: 110 mg twice daily.
    • CrCl <30 mL/min: Dabigatran is generally not recommended.
• Major Trial: RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy)
  • Design: A randomized trial comparing Dabigatran with Warfarin in patients with non-valvular atrial fibrillation.
  • Participants: 18,113 patients with AF.
  • Findings:
    • Dabigatran 150 mg was superior to warfarin in reducing stroke and systemic embolism.
    • Dabigatran 110 mg was non-inferior to warfarin but had a lower risk of major bleeding.
    • Both doses of Dabigatran reduced the risk of intracranial hemorrhage compared to warfarin.
  • Conclusion: Dabigatran 150 mg is more effective than warfarin for stroke prevention, while the 110 mg dose offers a safer alternative with a lower bleeding risk.

• Related Diseases and Common Drug Interactions:

  1. Atrial Fibrillation (AF):
     • Drug interactions:
       • P-gp inhibitors (e.g., Amiodarone, Verapamil, Dronedarone) are common in AF management. These drugs increase Dabigatran levels, raising the risk of bleeding.
       • NSAIDs like Aspirin are frequently used for pain or inflammation in AF patients, but they increase the risk of gastrointestinal bleeding when combined with Dabigatran.
  2. Coronary Artery Disease (CAD) (which can occur with AF):
     • Antiplatelet agents such as Aspirin or Clopidogrel are often used but increase bleeding risk when combined with Dabigatran.
  3. Pulmonary Embolism (PE):
     • P-gp inducers (e.g., Rifampin, Phenytoin) may be used in treating associated infections or seizures. These reduce Dabigatran levels and can increase the risk of recurrent thrombosis.
  4. Deep Vein Thrombosis (DVT):
     • Antibiotics like Clarithromycin, used in infections (often common in post-surgical DVT patients), increase Dabigatran levels, raising the bleeding risk.

Rivaroxaban (Xarelto):

• Mechanism: Direct Factor Xa inhibitor.
• Indications: Stroke prevention in atrial fibrillation, DVT, PE, and prevention after surgery.
• Dosage:
  • Normal Dose: 20 mg once daily.
    • Rivaroxaban 20 mg once daily is the standard dose for stroke prevention in atrial fibrillation.
  • Lower Dose (Renal Impairment or specific populations):
    • Asian population: 15 mg once daily (this dose is often preferred based on studies showing similar efficacy with lower bleeding risks in Asian patients).
    • Renal impairment (CrCl 15-50 mL/min): 15 mg once daily.
  • Severe Renal Impairment (CrCl <15 mL/min): Rivaroxaban is not recommended.
• Major Trial: ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
  • Design: A randomized, double-blind trial comparing Rivaroxaban with Warfarin.
  • Participants: 14,264 patients with non-valvular atrial fibrillation.
  • Findings:
    • Rivaroxaban was non-inferior to warfarin in preventing stroke and systemic embolism.
    • It had a lower risk of intracranial hemorrhage and fatal bleeding compared to warfarin.
    • Gastrointestinal bleeding was more common with Rivaroxaban than with warfarin.
  • Conclusion: Rivaroxaban is a non-inferior alternative to warfarin with a better safety profile regarding intracranial bleeding, but it has a higher risk of gastrointestinal bleeding.

• Related Diseases and Common Drug Interactions:

  1. Atrial Fibrillation (AF):
     • P-gp and CYP3A4 inhibitors (e.g., Dronedarone, Ritonavir) increase Rivaroxaban levels, which can cause bleeding. These drugs are used in AF or AF-related conditions.
     • NSAIDs like Ibuprofen and Naproxen for musculoskeletal pain increase the risk of gastrointestinal bleeding.
  2. Coronary Artery Disease (CAD) (common with AF):
     • Statins (e.g., Atorvastatin), used for cholesterol control in CAD, may interact with Rivaroxaban when metabolized by CYP3A4. Close monitoring is required to prevent adverse effects.
  3. Pulmonary Embolism (PE):
     • Antibiotics like Clarithromycin (strong CYP3A4 inhibitors) can raise Rivaroxaban levels, increasing the bleeding risk, especially in PE patients who require long-term anticoagulation.
  4. Deep Vein Thrombosis (DVT):
     • CYP3A4 inducers (e.g., Rifampin, Phenytoin) lower Rivaroxaban levels, reducing its efficacy and raising the risk of recurrent DVT.

Apixaban (Eliquis):

• Mechanism: Direct Factor Xa inhibitor.
• Indications: Stroke prevention in AF, DVT, PE.
• Dosage:
  • Normal Dose: 5 mg twice daily.
    • Apixaban 5 mg twice daily is the standard dose for stroke prevention in atrial fibrillation.
  • Lower Dose: 2.5 mg twice daily.
    • Use this lower dose if the patient meets two or more of the following criteria:
      • Age ≥ 80 years.
      • Body weight ≤ 60 kg.
      • Serum creatinine ≥ 1.5 mg/dL.
    • Apixaban 2.5 mg twice daily is also used in patients with significant renal impairment (CrCl 15-30 mL/min).
  • Severe Renal Impairment (CrCl <15 mL/min): Apixaban is generally not recommended.
• Major Trial: ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)
  • Design: A randomized, double-blind trial comparing Apixaban with Warfarin.
  • Participants: 18,201 patients with AF.
  • Findings:
    • Apixaban was superior to warfarin for reducing stroke and systemic embolism.
    • It was associated with significantly lower risk of major bleeding, including intracranial hemorrhage.
    • Mortality rates were also lower with Apixaban compared to warfarin.
  • Conclusion: Apixaban is superior to warfarin for both efficacy and safety, with lower risks of stroke, bleeding, and overall mortality.

• Related Diseases and Common Drug Interactions:

  1. Atrial Fibrillation (AF):
     • P-gp and CYP3A4 inhibitors (e.g., Ketoconazole, Dronedarone) increase Apixaban levels, leading to increased bleeding risk. These drugs are used in managing AF and fungal infections.
     • NSAIDs like Aspirin increase the risk of bleeding when taken with Apixaban, which is a common scenario in AF patients who may also have CAD or musculoskeletal pain.
  2. Coronary Artery Disease (CAD):
     • Clopidogrel (an antiplatelet used in CAD) increases the bleeding risk when combined with Apixaban. Dual therapy (anticoagulant + antiplatelet) requires careful monitoring.
  3. Pulmonary Embolism (PE):
     • Antibiotics like Erythromycin (CYP3A4 inhibitors) increase Apixaban levels and bleeding risk in PE patients, especially those on long-term anticoagulation therapy.
  4. Deep Vein Thrombosis (DVT):
     • CYP3A4 inducers (e.g., Rifampin, Carbamazepine) reduce Apixaban levels, making it less effective in preventing recurrent DVT.

Edoxaban (Savaysa):

• Mechanism: Direct Factor Xa inhibitor.
• Indications: Stroke prevention in AF, DVT, PE.
• Dosage:
  • Normal Dose: 60 mg once daily.
    • Edoxaban 60 mg once daily is the standard dose for stroke prevention in atrial fibrillation.
  • Lower Dose: 30 mg once daily.
    • Used in patients with the following characteristics:
      • CrCl 15-50 mL/min.
      • Body weight ≤ 60 kg.
      • Concurrent use of potent P-glycoprotein inhibitors (e.g., verapamil, dronedarone, quinidine).
  • Severe Renal Impairment (CrCl <15 mL/min): Edoxaban is not recommended.
• Major Trial: ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)
  • Design: A randomized, double-blind trial comparing two doses of Edoxaban (60 mg and 30 mg) with Warfarin.
  • Participants: 21,105 patients with AF.
  • Findings:
    • Both doses of Edoxaban were non-inferior to warfarin for stroke and systemic embolism prevention.
    • The higher dose of Edoxaban (60 mg) had a lower risk of stroke compared to warfarin.
    • Both doses had significantly lower rates of major bleeding and intracranial hemorrhage compared to warfarin.
    • The lower dose (30 mg) was associated with higher rates of ischemic stroke but had a reduced bleeding risk.
  • Conclusion: Edoxaban provides an effective and safer alternative to warfarin, with reduced rates of bleeding and intracranial hemorrhage, though careful dose adjustments are critical.

• Related Diseases and Common Drug Interactions:

  1. Atrial Fibrillation (AF):
     • P-gp inhibitors like Verapamil, Dronedarone, and Ritonavir increase Edoxaban levels, leading to increased bleeding risks. Verapamil and Dronedarone are often used in AF management.
  2. Coronary Artery Disease (CAD):
     • Clopidogrel or Aspirin, used in CAD for antiplatelet therapy, increases the risk of bleeding when combined with Edoxaban.
  3. Pulmonary Embolism (PE):
     • Antibiotics like Rifampin (P-gp inducer) reduce Edoxaban levels, leading to decreased efficacy and a higher risk of recurrent PE.
  4. Deep Vein Thrombosis (DVT):
     • CYP3A4 and P-gp inducers (e.g., Phenytoin, Carbamazepine) reduce Edoxaban levels, making it less effective for DVT prevention and increasing the risk of recurrence.

---

4. Summary of Findings:

• Efficacy:
  • Dabigatran 150 mg and Apixaban were superior to warfarin for stroke prevention.
  • Rivaroxaban and Edoxaban were non-inferior to warfarin.
• Bleeding Risk:
  • All NOACs had a lower risk of intracranial hemorrhage compared to warfarin.
  • Apixaban and Edoxaban had lower overall bleeding risks.
  • Rivaroxaban had a higher risk of gastrointestinal bleeding.

---

Conclusion:

DOACs (NOACs) have emerged as first-line therapies for stroke prevention in atrial fibrillation and for the treatment of venous thromboembolism, largely replacing warfarin due to their similar or superior efficacy, more predictable action, and reduced need for regular monitoring. Among the NOACs, Apixaban stands out as particularly effective for both efficacy and safety, while Dabigatran, Rivaroxaban, and Edoxaban provide excellent alternatives depending on patient factors like renal function and bleeding risk.